389 related articles for article (PubMed ID: 28332364)
1. Potential Antitumor Activity of SIM-89 in Non-Small Cell Lung Cancer Cells.
Pei J; Chu T; Shao M; Teng J; Sha H; Gu A; Li R; Qian J; Mao W; Li Y; Han B
Yonsei Med J; 2017 May; 58(3):581-591. PubMed ID: 28332364
[TBL] [Abstract][Full Text] [Related]
2. Met tyrosine kinase inhibitor, PF-2341066, suppresses growth and invasion of nasopharyngeal carcinoma.
Zhao Y; Zhang J; Tian Y; Xue C; Hu Z; Zhang L
Drug Des Devel Ther; 2015; 9():4897-907. PubMed ID: 26345996
[TBL] [Abstract][Full Text] [Related]
3. Combining onartuzumab with erlotinib inhibits growth of non-small cell lung cancer with activating EGFR mutations and HGF overexpression.
Sano Y; Hashimoto E; Nakatani N; Abe M; Satoh Y; Sakata K; Fujii T; Fujimoto-Ouchi K; Sugimoto M; Nagahashi S; Aoki M; Motegi H; Sasaki E; Yatabe Y
Mol Cancer Ther; 2015 Feb; 14(2):533-41. PubMed ID: 25522765
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of tumor growth and metastasis in non-small cell lung cancer by LY2801653, an inhibitor of several oncokinases, including MET.
Wu W; Bi C; Credille KM; Manro JR; Peek VL; Donoho GP; Yan L; Wijsman JA; Yan SB; Walgren RA
Clin Cancer Res; 2013 Oct; 19(20):5699-710. PubMed ID: 23989980
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of tumor cell growth, invasion, and metastasis by EXEL-2880 (XL880, GSK1363089), a novel inhibitor of HGF and VEGF receptor tyrosine kinases.
Qian F; Engst S; Yamaguchi K; Yu P; Won KA; Mock L; Lou T; Tan J; Li C; Tam D; Lougheed J; Yakes FM; Bentzien F; Xu W; Zaks T; Wooster R; Greshock J; Joly AH
Cancer Res; 2009 Oct; 69(20):8009-16. PubMed ID: 19808973
[TBL] [Abstract][Full Text] [Related]
6. Metformin reduces HGF-induced resistance to alectinib via the inhibition of Gab1.
Chen H; Lin C; Peng T; Hu C; Lu C; Li L; Wang Y; Han R; Feng M; Sun F; He Y
Cell Death Dis; 2020 Feb; 11(2):111. PubMed ID: 32041944
[TBL] [Abstract][Full Text] [Related]
7. Targeting the MET gene for the treatment of non-small-cell lung cancer.
Gelsomino F; Facchinetti F; Haspinger ER; Garassino MC; Trusolino L; De Braud F; Tiseo M
Crit Rev Oncol Hematol; 2014 Feb; 89(2):284-99. PubMed ID: 24355409
[TBL] [Abstract][Full Text] [Related]
8. A selective c-met inhibitor blocks an autocrine hepatocyte growth factor growth loop in ANBL-6 cells and prevents migration and adhesion of myeloma cells.
Hov H; Holt RU; Rø TB; Fagerli UM; Hjorth-Hansen H; Baykov V; Christensen JG; Waage A; Sundan A; Børset M
Clin Cancer Res; 2004 Oct; 10(19):6686-94. PubMed ID: 15475459
[TBL] [Abstract][Full Text] [Related]
9. The HGF inhibitory peptide HGP-1 displays promising in vitro and in vivo efficacy for targeted cancer therapy.
Chen L; Li C; Zhu Y
Oncotarget; 2015 Oct; 6(30):30088-101. PubMed ID: 26254225
[TBL] [Abstract][Full Text] [Related]
10. Leukocyte Cell-Derived Chemotaxin 2 Retards Non-Small Cell Lung Cancer Progression Through Antagonizing MET and EGFR Activities.
Hung WY; Chang JH; Cheng Y; Chen CK; Chen JQ; Hua KT; Cheng CW; Hsiao M; Chung CL; Lee WJ; Chien MH
Cell Physiol Biochem; 2018; 51(1):337-355. PubMed ID: 30453282
[TBL] [Abstract][Full Text] [Related]
11. α-Lipoic acid-induced inhibition of proliferation and met phosphorylation in human non-small cell lung cancer cells.
Michikoshi H; Nakamura T; Sakai K; Suzuki Y; Adachi E; Matsugo S; Matsumoto K
Cancer Lett; 2013 Jul; 335(2):472-8. PubMed ID: 23507559
[TBL] [Abstract][Full Text] [Related]
12. The combination of multiple receptor tyrosine kinase inhibitor and mammalian target of rapamycin inhibitor overcomes erlotinib resistance in lung cancer cell lines through c-Met inhibition.
Nakachi I; Naoki K; Soejima K; Kawada I; Watanabe H; Yasuda H; Nakayama S; Yoda S; Satomi R; Ikemura S; Terai H; Sato T; Ishizaka A
Mol Cancer Res; 2010 Aug; 8(8):1142-51. PubMed ID: 20647329
[TBL] [Abstract][Full Text] [Related]
13. A selective small molecule inhibitor of c-Met kinase inhibits c-Met-dependent phenotypes in vitro and exhibits cytoreductive antitumor activity in vivo.
Christensen JG; Schreck R; Burrows J; Kuruganti P; Chan E; Le P; Chen J; Wang X; Ruslim L; Blake R; Lipson KE; Ramphal J; Do S; Cui JJ; Cherrington JM; Mendel DB
Cancer Res; 2003 Nov; 63(21):7345-55. PubMed ID: 14612533
[TBL] [Abstract][Full Text] [Related]
14. MET tyrosine kinase inhibitor crizotinib (PF-02341066) shows differential antitumor effects in non-small cell lung cancer according to MET alterations.
Tanizaki J; Okamoto I; Okamoto K; Takezawa K; Kuwata K; Yamaguchi H; Nakagawa K
J Thorac Oncol; 2011 Oct; 6(10):1624-31. PubMed ID: 21716144
[TBL] [Abstract][Full Text] [Related]
15. Anti-c-MET Nanobody - a new potential drug in multiple myeloma treatment.
Slørdahl TS; Denayer T; Moen SH; Standal T; Børset M; Ververken C; Rø TB
Eur J Haematol; 2013 Nov; 91(5):399-410. PubMed ID: 23952536
[TBL] [Abstract][Full Text] [Related]
16. Quercetin inhibits HGF/c-Met signaling and HGF-stimulated melanoma cell migration and invasion.
Cao HH; Cheng CY; Su T; Fu XQ; Guo H; Li T; Tse AK; Kwan HY; Yu H; Yu ZL
Mol Cancer; 2015 May; 14():103. PubMed ID: 25971889
[TBL] [Abstract][Full Text] [Related]
17. PHA665752, a small-molecule inhibitor of c-Met, inhibits hepatocyte growth factor-stimulated migration and proliferation of c-Met-positive neuroblastoma cells.
Crosswell HE; Dasgupta A; Alvarado CS; Watt T; Christensen JG; De P; Durden DL; Findley HW
BMC Cancer; 2009 Nov; 9():411. PubMed ID: 19939254
[TBL] [Abstract][Full Text] [Related]
18. BMS-777607, a small-molecule met kinase inhibitor, suppresses hepatocyte growth factor-stimulated prostate cancer metastatic phenotype in vitro.
Dai Y; Siemann DW
Mol Cancer Ther; 2010 Jun; 9(6):1554-61. PubMed ID: 20515943
[TBL] [Abstract][Full Text] [Related]
19. Shikonin Inhibited Migration and Invasion of Human Lung Cancer Cells via Suppression of c-Met-Mediated Epithelial-to-Mesenchymal Transition.
Hsieh YS; Liao CH; Chen WS; Pai JT; Weng MS
J Cell Biochem; 2017 Dec; 118(12):4639-4651. PubMed ID: 28485480
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of c-Met and prevention of spontaneous metastatic spreading by the 2-indolinone RPI-1.
Cassinelli G; Lanzi C; Petrangolini G; Tortoreto M; Pratesi G; Cuccuru G; Laccabue D; Supino R; Belluco S; Favini E; Poletti A; Zunino F
Mol Cancer Ther; 2006 Sep; 5(9):2388-97. PubMed ID: 16985073
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]